199 related articles for article (PubMed ID: 30229873)
1. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
[No Abstract] [Full Text] [Related]
2. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ; Ascierto PA; Carlino MS; Gershenwald JE; Grob JJ; Hauschild A; Kirkwood JM; Long GV; Mohr P; Robert C; Ross M; Scolyer RA; Yoon CH; Poklepovic A; Rutkowski P; Anderson JR; Ahsan S; Ibrahim N; M Eggermont AM
Future Oncol; 2020 Jan; 16(3):4429-4438. PubMed ID: 31870188
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
[TBL] [Abstract][Full Text] [Related]
4. Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma.
Cinotti E; Fiorani D; Provvidenziale L; Miracco C; Calamai V; Danielli R; Rubegni P
Int J Dermatol; 2019 Jul; 58(7):e138-e140. PubMed ID: 30810218
[No Abstract] [Full Text] [Related]
5. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor.
Horii M; Kobayashi T; Maeda S; Takehara K; Matsushita T
J Dermatol; 2019 Nov; 46(11):e434-e436. PubMed ID: 31342541
[No Abstract] [Full Text] [Related]
8. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
Mauzo SH; Tetzlaff MT; Nelson K; Amaria R; Patel S; Aung PP; Nagarajan P; Torres-Cabala CA; Diab A; Prieto VG; Curry JL
Int J Dermatol; 2019 Sep; 58(9):1045-1052. PubMed ID: 29152725
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic flow is mostly preserved after sentinel lymph node biopsy in primary cutaneous malignant melanoma.
Yokota K; Sawada M; Matsumoto T; Hasegawa Y; Kono M; Akiyama M
J Dermatol Sci; 2015 May; 78(2):101-7. PubMed ID: 25771166
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
11. Completion Node Dissection After Sentinel Node Biopsy in Melanoma.
Delman KA; Wong SL
JAMA Surg; 2018 Nov; 153(11):1045-1046. PubMed ID: 30027279
[No Abstract] [Full Text] [Related]
12. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
13. Is it metastatic melanoma or is it sarcoidosis? Non-caseating granulomas due to pembrolizumab.
Chahin M; Stack A; Siddiqi A; Shaikh M
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33371005
[No Abstract] [Full Text] [Related]
14. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
15. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
Eur J Cancer; 2019 Mar; 110():49-52. PubMed ID: 30739840
[No Abstract] [Full Text] [Related]
16. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
17. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
[No Abstract] [Full Text] [Related]
18. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
19. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
20. Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma.
Stuart L; Lambourne B; Turner P; Jones DEJ; Plummer R; Cresti N; Dyson JK
Hepatology; 2020 Jun; 71(6):2164-2166. PubMed ID: 31872447
[No Abstract] [Full Text] [Related]
[Next] [New Search]